Dose selection for radioiodine therapy of borderline hyperthyroid patients according to thyroid uptake of 99mTc-pertechnetate: applicability to unifocal thyroid autonomy?

2006 ◽  
Vol 33 (5) ◽  
pp. 608-612 ◽  
Author(s):  
Michael J. Reinhardt ◽  
Kim Biermann ◽  
Michael Wissmeyer ◽  
Freimut D. Juengling ◽  
Holger Brockmann ◽  
...  
2018 ◽  
Vol 19 (2) ◽  
pp. 89
Author(s):  
Sadia Hossain ◽  
Sanowar Hossain ◽  
Fatema S Haque ◽  
Shanker K Biswas ◽  
Rubina Begum ◽  
...  

<p><strong>Objectives</strong>: With the advancement of science, the scope of 131 I thyroid uptake in diagnosis and treatment of thyroid diseases has become limited. Uptake test with 99m Technetium (99mTc) pertechnetate along with a thyroid scan, which are done almost routinely, could be a better option when required. This will not only exempt the patients from relatively higher radiation burden of 131I but will also cause significant reduction of procedural time. Moreover, the thyroid image we get along with the uptake may guide with additional information. This study was done to provide preliminary data regarding thyroid uptake test with 99mTc in our population &amp; to assess the possibilities of introducing this safer and convenient radionuclide in our routine practice.<strong> </strong></p><p><strong>Patients and methods:</strong> This cross sectional, comparative study was conducted from January to December of 2015 on 27 participants in Institute of Nuclear Medicine and Allied Sciences, Dhaka. Hyperthyroid patients coming for a radioactive iodine uptake test along with a thyroid scan were enrolled. Uptake of 99mTc pertechnetate at 20 minutes and 131I at 24 hours were measured.  </p><p><strong>Results: </strong>Among 27 participants, 25 had raised, 2 had normal 131I uptake. Two normal values of 99m Tc uptake were found and rest showed high uptake. Two patients had high uptakes in both the method but 131 I uptake was extremely high (90% and 80%) in comparison to 99mTc uptake (10% and 7% respectively). Statistical analysis revealed a moderate agreement (k=0.5) along with a moderate positive correlation (r=0.6) between the two uptake methods.</p><p><strong>Conclusion:</strong> Good agreement and correlation were found between two modalities of thyroid uptake in case of hyperthyroid patients. So, 99mTc may be considered for uptake test in a regular basis in the limited fields where an uptake is still required as it may yield a reliable result in a simple, quicker and more convenient way.</p><p>Bangladesh J. Nuclear Med. 19(2): 89-91, July 2016</p>


2002 ◽  
Vol 41 (06) ◽  
pp. 245-251 ◽  
Author(s):  
M. Knietsch ◽  
T. Spillmann ◽  
E.-G. Grünbaum ◽  
R. Bauer ◽  
M. Puille

SummaryAim: Establishment of radioiodine treatment of feline hyperthyroidism in veterinary routine in accordance with German radiation protection regulations. Patients and methods: 35 cats with proven hyperthyroidism were treated with 131I in a special ward. Thyroid uptake and effective halflife were determined using gammacamera dosimetry. Patients were released when measured whole body activity was below the limit defined in the German “Strahlenschutzverordnung”. Results: 17/20 cats treated with 150 MBq radioiodine and 15/15 cats treated with 250 MBq had normal thyroid function after therapy, normal values for FT3 and FT4 were reached after two and normal TSH levels after three weeks. In 14 cats normal thyroid function was confirmed by controls 3-6 months later. Thyroidal iodine uptake was 24 ± 10%, effective halflife 2.5 ± 0.7 days. Whole body activity <1 MBq was reached 13 ± 4 days after application of 131I. Radiation exposure of cat owners was estimated as 1.97 Sv/MBq for adults. Conclusion: Radioiodine therapy of feline hyper-thyroidism is highly effective and safe. It can easily be performed in accordance with German radiation protection regulations, although this requires hospitalisation for approximately two weeks. Practical considerations on radiation exposure of cat owners do not justify this long interval. Regulations for the veterinary use of radioactive substances similar to existing regulations for medical use in humans are higly desirable.


2018 ◽  
Vol 20 (1) ◽  
pp. 37
Author(s):  
Sharmin Quddus ◽  
Fatima Begum ◽  
Nasreen Sultana ◽  
Rahima Perveen ◽  
Tapati Mandal ◽  
...  

<p><strong>Objective:</strong> The modified fixed doses of radioactive iodine (RAI) in different types of hyperthyroidism had been practiced at National Institute of Nuclear Medicine &amp; Allied Science (NINMAS) according to Society of Nuclear Medicine Bangladesh (SNMB) protocol since 2002 which was upgraded in 2015. The objective of the study was to observe the treatment outcome in modified fixed dose on previous protocol. Patients and Methods: In the present study the outcome of radioiodine therapy of hyperthyroid patients was retrospectively evaluated in 1349 consecutive primary hyperthyroid patients treated from January 2010 to December 2014 at NINMAS. Diagnosis of hyperthyroidism was done by thyroid function test; thyroid stimulating hormone (TSH), free triiodothyronine (FT3)   &amp; free thyroxine (FT4), 99m Technetium scan, thyroid radioiodine uptake and ultrasound imaging of thyroid gland. All patients received a fixed dose (8-29 m Ci) of radioactive iodine (RAI) depending on types of hyperthyroidism, visual assessment of gland size and severity of disease at diagnosis. They were followed up at 2 months of therapy, then every three months intervals for first year and thereafter 6 monthly up to 5 years or as needed during fluctuation of thyroid function.</p><p><strong>Results:</strong> Among the study population, 832 patients had diffuse toxic goiter (Graves’ disease), 369 patients were diagnosed as toxic multinodular goiter and 148 patients with single toxic nodule. At one year follow-up, permanent hypothyroidism occurred in 61.62% of patients and the cumulative incidence of hypothyroidism progressively increased up to 79.25% after 5 years. Cure or success of RAI therapy was considered as attainment of euthyroid state or hypothyroid state. About 11.26 % patients received more than single dose.</p><p><strong>Conclusion:</strong> Fixed dose RAI therapy is very much cost effective mode of treatment for primary hyperthyroidism with ~89% success by giving single dose.</p><p>Bangladesh J. Nuclear Med. 20(1): 37-40, January 2017</p>


2006 ◽  
Vol 40 (7) ◽  
pp. 587-591 ◽  
Author(s):  
Bruce E. Sands ◽  
Karl M. Kilgore ◽  
Richard S. Bloomfeld ◽  
William J. Sandborn

2015 ◽  
Vol 2 (suppl_1) ◽  
Author(s):  
Sujata M. Bhavnani ◽  
Paul G. Ambrose ◽  
Wolfgang W. Wicha ◽  
Zrinka Ivezic-Schoenfeld ◽  
William T. Prince ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document